JP5057990B2 - 線維筋痛症候群の治療のためのアセチルｌ−カルニチンの使用 - Google Patents
線維筋痛症候群の治療のためのアセチルｌ−カルニチンの使用 Download PDFInfo
- Publication number
- JP5057990B2 JP5057990B2 JP2007544754A JP2007544754A JP5057990B2 JP 5057990 B2 JP5057990 B2 JP 5057990B2 JP 2007544754 A JP2007544754 A JP 2007544754A JP 2007544754 A JP2007544754 A JP 2007544754A JP 5057990 B2 JP5057990 B2 JP 5057990B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- carnitine
- acetyl
- treatment
- fibromyalgia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title claims abstract description 21
- 208000001640 Fibromyalgia Diseases 0.000 title claims description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 20
- -1 mucate Chemical compound 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 241000219061 Rheum Species 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000606A ITRM20040606A1 (it) | 2004-12-13 | 2004-12-13 | Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica. |
| ITRM2004A000606 | 2004-12-13 | ||
| PCT/EP2005/012054 WO2006063639A1 (en) | 2004-12-13 | 2005-11-10 | Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534433A JP2008534433A (ja) | 2008-08-28 |
| JP2008534433A5 JP2008534433A5 (enExample) | 2008-12-25 |
| JP5057990B2 true JP5057990B2 (ja) | 2012-10-24 |
Family
ID=35708966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544754A Expired - Fee Related JP5057990B2 (ja) | 2004-12-13 | 2005-11-10 | 線維筋痛症候群の治療のためのアセチルｌ−カルニチンの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8013016B2 (enExample) |
| EP (1) | EP1824472B1 (enExample) |
| JP (1) | JP5057990B2 (enExample) |
| KR (1) | KR101240182B1 (enExample) |
| AT (1) | ATE419847T1 (enExample) |
| CA (1) | CA2585560C (enExample) |
| CY (1) | CY1110576T1 (enExample) |
| DE (1) | DE602005012317D1 (enExample) |
| DK (1) | DK1824472T3 (enExample) |
| ES (1) | ES2320788T3 (enExample) |
| IT (1) | ITRM20040606A1 (enExample) |
| MX (1) | MX2007006954A (enExample) |
| PL (1) | PL1824472T3 (enExample) |
| PT (1) | PT1824472E (enExample) |
| SI (1) | SI1824472T1 (enExample) |
| WO (1) | WO2006063639A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2840363A1 (en) * | 2011-06-24 | 2012-12-27 | K-Pax Pharmaceuticals, Inc. | Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue |
| ES2962933T3 (es) | 2020-12-14 | 2024-03-21 | Ims Gear Se & Co Kgaa | Procedimiento para la corrección de una señal de medición dependiente del tiempo de una unidad de motor-engranaje, así como procedimiento para detectar desgaste y/o un deterioro de la misma mediante este procedimiento de corrección |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1150396B (it) * | 1982-12-09 | 1986-12-10 | Sigma Tau Ind Farmaceuti | Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari |
| EP0681839A3 (en) * | 1994-05-12 | 1997-11-12 | Hirohiko Kuratsune | A pharmaceutical preparation comprising an acylcarnitine |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US5935949A (en) * | 1998-03-20 | 1999-08-10 | Trustees Of Dartmouth College | Use of androgen therapy in fibromyalgia and chronic fatigue syndrome |
| US6803387B1 (en) | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
| ITRM20010293A1 (it) | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore. |
| KR101027570B1 (ko) * | 2002-05-03 | 2011-04-06 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물 |
-
2004
- 2004-12-13 IT IT000606A patent/ITRM20040606A1/it unknown
-
2005
- 2005-11-10 SI SI200530579T patent/SI1824472T1/sl unknown
- 2005-11-10 US US11/719,447 patent/US8013016B2/en not_active Expired - Fee Related
- 2005-11-10 CA CA2585560A patent/CA2585560C/en not_active Expired - Fee Related
- 2005-11-10 JP JP2007544754A patent/JP5057990B2/ja not_active Expired - Fee Related
- 2005-11-10 AT AT05807584T patent/ATE419847T1/de active
- 2005-11-10 PL PL05807584T patent/PL1824472T3/pl unknown
- 2005-11-10 MX MX2007006954A patent/MX2007006954A/es active IP Right Grant
- 2005-11-10 WO PCT/EP2005/012054 patent/WO2006063639A1/en not_active Ceased
- 2005-11-10 EP EP05807584A patent/EP1824472B1/en not_active Expired - Lifetime
- 2005-11-10 DE DE602005012317T patent/DE602005012317D1/de not_active Expired - Lifetime
- 2005-11-10 PT PT05807584T patent/PT1824472E/pt unknown
- 2005-11-10 DK DK05807584T patent/DK1824472T3/da active
- 2005-11-10 KR KR1020077015272A patent/KR101240182B1/ko not_active Expired - Fee Related
- 2005-11-10 ES ES05807584T patent/ES2320788T3/es not_active Expired - Lifetime
-
2009
- 2009-03-31 CY CY20091100383T patent/CY1110576T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1824472B1 (en) | 2009-01-07 |
| ITRM20040606A1 (it) | 2005-03-13 |
| ATE419847T1 (de) | 2009-01-15 |
| US20090076146A1 (en) | 2009-03-19 |
| KR101240182B1 (ko) | 2013-03-07 |
| KR20070091317A (ko) | 2007-09-10 |
| CY1110576T1 (el) | 2015-04-29 |
| CA2585560C (en) | 2013-01-08 |
| PL1824472T3 (pl) | 2009-05-29 |
| SI1824472T1 (sl) | 2009-04-30 |
| ES2320788T3 (es) | 2009-05-28 |
| MX2007006954A (es) | 2007-08-02 |
| EP1824472A1 (en) | 2007-08-29 |
| CA2585560A1 (en) | 2006-06-22 |
| WO2006063639A1 (en) | 2006-06-22 |
| DK1824472T3 (da) | 2009-03-30 |
| JP2008534433A (ja) | 2008-08-28 |
| PT1824472E (pt) | 2009-03-31 |
| DE602005012317D1 (de) | 2009-02-26 |
| US8013016B2 (en) | 2011-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152058A1 (en) | Methods and compositions for treating various disorders | |
| PT2322225E (pt) | Inibidores selectivos da recaptação da serotonina e da norepinefrina para tratamento de síndrome de fibromialgia, síndrome da fadiga crónica e dor | |
| US20200323823A1 (en) | Methods for the treatment of depression | |
| US20180051017A1 (en) | Agent for treatment of schizophrenia | |
| Höckerstedt et al. | Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation | |
| Rollinson et al. | Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate | |
| JP5057990B2 (ja) | 線維筋痛症候群の治療のためのアセチルｌ−カルニチンの使用 | |
| EP1569635B1 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
| JP2005523269A (ja) | 老人性うつ病の治療におけるカルニチン | |
| US20080161604A1 (en) | Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| US7776913B2 (en) | Carnitines for treating or preventing disorders caused by andropause | |
| KR101176347B1 (ko) | 당뇨병 환자의 신경병 통증 치료용 약제의 제조를 위한아세틸 엘 카르니틴의 용도 | |
| HUP0302371A2 (hu) | Béta-blokkolót és adott esetben koleszterinszint-csökkentőt tartalmazó új gyógyszerkészítmény | |
| EP1519719A1 (en) | Methods for the treatment of sinusitis | |
| JP2009235018A (ja) | 線維筋痛症治療剤 | |
| Pain | A Association | |
| Lorenzi et al. | BRUXISM: DIAGNOSIS AND TREATMENT, A NARRATIVE REVIEW |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120223 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120703 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120731 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150810 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |